[Therapeutic effect of autologous cytokine-induced killer cells on patients with liver cirrhosis caused by HBV infection].
OBJECTIVE
To observe the therapeutic effect of autologous cytokine-induced killer cells (CIK) on HBV DNA positive patients with liver cirrhosis.


METHODS
HBV DNA positive 33 patients with cirrhosis were treated with CIK. Before and after cultured in vitro and post-treatment, CD3+, CD3+CD4+, CD3+CD8+, CD3+CD56+ cells, mDC and pDC were detected by flow cytometry. The indexes of virus and liver function were compared between pre- and post-treatment.


RESULTS
CD3+, CD3+CD8+ cells and CD3+CD56+ cells were higher after cultured in vitro and after transfused back than those before culture (91.5 +/- 10.3, 74.4 +/- 9.9 vs. 67.9 +/- 12.8; 60.9 +/- 15.5, 37.3 +/- 15.1 vs. 27.9 +/- 10.9; 18.4 +/- 11.7, 14.5 +/- 7.5 vs. 10.6 +/- 7.1). The percentages of mDC and pDC also increased after-treatment vs. pre-treatment (0.54 +/- 0.18 vs. 0.70 +/- 0.29; 0.26 +/- 0.13 vs. 0.41 +/- 0.25). HBV DNA became undetectable in 12 patients and decrease exceeded 100 times in 4 patients after treatment. HBeAg became undetectable in 10 of 14 patients who were HBeAg positive pretreatment patients, among them 2 patients had HBeAb sero conversion. The liver function was improved after treatment. All patients tolerated the treatment.


CONCLUSIONS
CIK treatment can increase immune effector cells and has some antiviral effect and is safe.
Su
Hai-bin
HB
The No. 302 Hospital of the People's Liberation Army, Beijing 100039, China.
Li
Han-wei
HW
Zhao
Hong-lan
HL
Shi
Ming
M
Zhang
Bing
B
Tang
Zi-rong
ZR
Lei
Zhou-yun
ZY
Wang
Hui-fen
HF
Wang
Fu-sheng
FS
D019264:Adoptive Transfer / Q000009:adverse effects / Q000379:methods*; D000328:Adult; D000368:Aged; D002478:Cells, Cultured; D055612:Cytokine-Induced Killer Cells / Q000166:cytology / Q000276:immunology / Q000637:transplantation*; D005221:Fatigue / Q000209:etiology; D005260:Female; D006261:Headache / Q000209:etiology; D006509:Hepatitis B / Q000150:complications* / Q000821:virology; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D014182:Transplantation, Autologous; D016896:Treatment Outcome